Literature DB >> 27141340

The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers.

François Bertucci1, Pascal Finetti2, Daniel Birnbaum2, Emilie Mamessier2.   

Abstract

Analysis of PDL1 mRNA expression in ∼5,500 breast cancers showed PDL1 upregulation in 38% of basal tumors and 38% of inflammatory breast cancers (IBC). Upregulation, associated with signs of strong cytotoxic local immune response, was associated with a better survival in the basal or triple-negative subtypes, and with a better pathological response to chemotherapy in these subtypes and IBC. Reactivation of dormant tumor-infiltrating lymphocytes (TILs) by PD1/PDL1-inhibitors represents a promising strategy in these aggressive tumors.

Entities:  

Keywords:  Breast cancer; PDL1; chemotherapy; immune response; inflammatory breast cancer; survival; triple-negative

Year:  2015        PMID： 27141340      PMCID： PMC4839307          DOI： 10.1080/2162402X.2015.1085148

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

1.  Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer.

Authors:  S Muenst; A R Schaerli; F Gao; S Däster; E Trella; R A Droeser; M G Muraro; P Zajac; R Zanetti; W E Gillanders; W P Weber; S D Soysal
Journal:  Breast Cancer Res Treat       Date:  2014-05-20       Impact factor: 4.872

2.  Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

Authors:  S Loi; S Michiels; R Salgado; N Sirtaine; V Jose; D Fumagalli; P-L Kellokumpu-Lehtinen; P Bono; V Kataja; C Desmedt; M J Piccart; S Loibl; C Denkert; M J Smyth; H Joensuu; C Sotiriou
Journal:  Ann Oncol       Date:  2014-03-07       Impact factor: 32.976

Review 3.  Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Francesca Castoldi; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Aurélien Marabelle; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-03-02       Impact factor: 8.110

4.  High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma.

Authors:  Jocelyne Jacquemier; François Bertucci; Pascal Finetti; Benjamin Esterni; Emmanuelle Charafe-Jauffret; Marie-Laure Thibult; Gilles Houvenaeghel; Benoit Van den Eynde; Daniel Birnbaum; Daniel Olive; Luc Xerri
Journal:  Int J Cancer       Date:  2012-01-01       Impact factor: 7.396

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.

Authors:  Kurt A Schalper; Vamsidhar Velcheti; Daniel Carvajal; Hallie Wimberly; Jason Brown; Lajos Pusztai; David L Rimm
Journal:  Clin Cancer Res       Date:  2014-03-19       Impact factor: 12.531

7.  Kinome expression profiling and prognosis of basal breast cancers.

Authors:  Renaud Sabatier; Pascal Finetti; Emilie Mamessier; Stéphane Raynaud; Nathalie Cervera; Eric Lambaudie; Jocelyne Jacquemier; Patrice Viens; Daniel Birnbaum; François Bertucci
Journal:  Mol Cancer       Date:  2011-07-21       Impact factor: 27.401

8.  Prognostic and predictive value of PDL1 expression in breast cancer.

Authors:  Renaud Sabatier; Pascal Finetti; Emilie Mamessier; José Adelaide; Max Chaffanet; Hamid Raza Ali; Patrice Viens; Carlos Caldas; Daniel Birnbaum; François Bertucci
Journal:  Oncotarget       Date:  2015-03-10

9.  PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.

Authors:  François Bertucci; Pascal Finetti; Cécile Colpaert; Emilie Mamessier; Maxime Parizel; Luc Dirix; Patrice Viens; Daniel Birnbaum; Steven van Laere
Journal:  Oncotarget       Date:  2015-05-30
  9 in total
  20 in total

1.  PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas.

Authors:  François Bertucci; Pascal Finetti; Delphine Perrot; Agnès Leroux; Françoise Collin; Axel Le Cesne; Jean-Michel Coindre; Jean-Yves Blay; Daniel Birnbaum; Emilie Mamessier
Journal:  Oncoimmunology       Date:  2017-02-08       Impact factor: 8.110

Review 2.  The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer.

Authors:  André Steven; Barbara Seliger
Journal:  Breast Care (Basel)       Date:  2018-02-02       Impact factor: 2.860

Review 3.  Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond.

Authors:  Cristina Migali; Monica Milano; Dario Trapani; Carmen Criscitiello; Angela Esposito; Marzia Locatelli; Ida Minchella; Giuseppe Curigliano
Journal:  Ther Adv Med Oncol       Date:  2016-07-10       Impact factor: 8.168

4.  The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.

Authors:  Yanchun Li; Mateusz Opyrchal; Song Yao; Xuan Peng; Li Yan; Hossam Jabbour; Thaer Khoury
Journal:  Breast Cancer Res Treat       Date:  2018-03-09       Impact factor: 4.872

Review 5.  Liquid Biopsies to Evaluate Immunogenicity of Gynecological/Breast Tumors: On the Way to Blood-Based Biomarkers for Immunotherapies.

Authors:  Corinna Keup; Rainer Kimmig; Sabine Kasimir-Bauer
Journal:  Breast Care (Basel)       Date:  2020-10-07       Impact factor: 2.860

6.  PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.

Authors:  Xinyu Ren; Huanwen Wu; Junliang Lu; Yuhan Zhang; Yufeng Luo; Qianqian Xu; Songjie Shen; Zhiyong Liang
Journal:  Cancer Biol Ther       Date:  2018-02-16       Impact factor: 4.742

7.  Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications.

Authors:  Jing He; Lei Huo; Junsheng Ma; Jun Zhao; Roland L Bassett; Xiaoping Sun; Naoto T Ueno; Bora Lim; Yun Gong
Journal:  Am J Clin Pathol       Date:  2018-02-17       Impact factor: 2.493

8.  HER2-targeted antibody-drug conjugate induces host immunity against cancer stem cells.

Authors:  Leiming Xia; Lu Wen; You Qin; Hannah E Dobson; Tao Zhang; Frank I Comer; Mary Jane Hinrichs; Michael D Oberst; Steven R Coats; Alfred E Chang; Yuanyuan Liu; Yangyi Bao; Fu Dai; Max S Wicha; Qiao Li
Journal:  Cell Chem Biol       Date:  2021-03-11       Impact factor: 8.116

Review 9.  Mechanism of immune evasion in breast cancer.

Authors:  Mozhi Wang; Changwang Zhang; Yongxi Song; Zhenning Wang; Yaojia Wang; Fang Luo; Yujie Xu; Yi Zhao; Zhonghua Wu; Yingying Xu
Journal:  Onco Targets Ther       Date:  2017-03-14       Impact factor: 4.147

10.  Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer.

Authors:  Yun-Feng Ma; Chen Chen; Dongqing Li; Min Liu; Zhuang-Wei Lv; Yanhong Ji; Jiru Xu
Journal:  Oncotarget       Date:  2017-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.